Amy Krambrink

850 total citations
15 papers, 655 citations indexed

About

Amy Krambrink is a scholar working on Virology, Infectious Diseases and Immunology. According to data from OpenAlex, Amy Krambrink has authored 15 papers receiving a total of 655 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Virology, 9 papers in Infectious Diseases and 4 papers in Immunology. Recurrent topics in Amy Krambrink's work include HIV Research and Treatment (11 papers), HIV/AIDS drug development and treatment (8 papers) and HIV/AIDS Research and Interventions (6 papers). Amy Krambrink is often cited by papers focused on HIV Research and Treatment (11 papers), HIV/AIDS drug development and treatment (8 papers) and HIV/AIDS Research and Interventions (6 papers). Amy Krambrink collaborates with scholars based in United States, South Africa and Cyprus. Amy Krambrink's co-authors include Zhaohui Su, Daniel J. Skiest, David M. Margolis, Daniel R. Kuritzkes, Roy M. Gulick, Diane V. Havlir, Scott Evans, K. R. Robertson, Timothy Wilkin and Paul R. Skolnik and has published in prestigious journals such as Neurology, Clinical Infectious Diseases and The Journal of Infectious Diseases.

In The Last Decade

Amy Krambrink

13 papers receiving 640 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Amy Krambrink United States 10 547 477 162 118 102 15 655
Ann Thorkelson United States 5 525 1.0× 371 0.8× 118 0.7× 99 0.8× 168 1.6× 6 617
Nitiya Chomchey Thailand 15 438 0.8× 508 1.1× 106 0.7× 278 2.4× 56 0.5× 33 706
Rebekah Puls Australia 16 425 0.8× 421 0.9× 157 1.0× 109 0.9× 88 0.9× 26 639
Chris Chung United States 9 717 1.3× 647 1.4× 52 0.3× 125 1.1× 121 1.2× 9 860
Frédéric Théodoro France 15 422 0.8× 375 0.8× 62 0.4× 229 1.9× 143 1.4× 25 723
Ana Canestri France 14 467 0.9× 501 1.1× 180 1.1× 230 1.9× 34 0.3× 35 754
Jerome H. Kim United States 12 698 1.3× 495 1.0× 220 1.4× 211 1.8× 98 1.0× 24 852
Lourdes Adamson United States 11 330 0.6× 244 0.5× 60 0.4× 99 0.8× 87 0.9× 18 416
Radjin Steingrover Netherlands 11 418 0.8× 381 0.8× 135 0.8× 89 0.8× 91 0.9× 15 530
Maria Concetta Bellocchi Italy 16 549 1.0× 571 1.2× 55 0.3× 183 1.6× 114 1.1× 42 850

Countries citing papers authored by Amy Krambrink

Since Specialization
Citations

This map shows the geographic impact of Amy Krambrink's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Amy Krambrink with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Amy Krambrink more than expected).

Fields of papers citing papers by Amy Krambrink

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Amy Krambrink. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Amy Krambrink. The network helps show where Amy Krambrink may publish in the future.

Co-authorship network of co-authors of Amy Krambrink

This figure shows the co-authorship network connecting the top 25 collaborators of Amy Krambrink. A scholar is included among the top collaborators of Amy Krambrink based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Amy Krambrink. Amy Krambrink is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

15 of 15 papers shown
1.
2.
Kirsner, Robert S., Irena Pastar, Amy Krambrink, et al.. (2025). Evaluation of c‐Myc and Phosphorylated Glucocorticoid Receptor (p‐ GR ) for Predicting Diabetic Foot Ulcer Healing—A Diabetic Foot Consortium Study. Wound Repair and Regeneration. 33(3). e70044–e70044. 1 indexed citations
3.
4.
Janes, Holly, Amy Krambrink, Rebecca J. Smith, et al.. (2013). Vaccine-Induced Gag-Specific T Cells Are Associated With Reduced Viremia After HIV-1 Infection. The Journal of Infectious Diseases. 208(8). 1231–1239. 49 indexed citations
5.
Robertson, K. R., Zhaohui Su, David M. Margolis, et al.. (2010). Neurocognitive effects of treatment interruption in stable HIV-positive patients in an observational cohort. Neurology. 74(16). 1260–1266. 167 indexed citations
6.
Schouten, Jeffrey T., Amy Krambrink, Heather J. Ribaudo, et al.. (2010). Substitution of Nevirapine because of Efavirenz Toxicity in AIDS Clinical Trials Group A5095. Clinical Infectious Diseases. 50(5). 787–791. 20 indexed citations
7.
Wilkin, Timothy, Zhaohui Su, Amy Krambrink, et al.. (2010). Three-Year Safety and Efficacy of Vicriviroc, a CCR5 Antagonist, in HIV-1–Infected Treatment-Experienced Patients. JAIDS Journal of Acquired Immune Deficiency Syndromes. 54(5). 470–476. 23 indexed citations
8.
Tsibris, Athe, Roger Paredes, Amy Chadburn, et al.. (2009). Lymphoma Diagnosis and Plasma Epstein‐Barr Virus Load during Vicriviroc Therapy: Results of the AIDS Clinical Trials Group A5211. Clinical Infectious Diseases. 48(5). 642–649. 14 indexed citations
9.
Su, Zhaohui, Roy M. Gulick, Amy Krambrink, et al.. (2009). Response to Vicriviroc in Treatment‐Experienced Subjects, as Determined by an Enhanced‐Sensitivity Coreceptor Tropism Assay: Reanalysis of AIDS Clinical Trials Group A5211. The Journal of Infectious Diseases. 200(11). 1724–1728. 42 indexed citations
10.
Vahey, Maryanne, Linghua Wang, Zhaohui Su, et al.. (2008). CD4 + T-Cell Decline after the Interruption of Antiretroviral Therapy in ACTG A5170 Is Predicted by Differential Expression of Genes in the Ras Signaling Pathway. AIDS Research and Human Retroviruses. 24(8). 1047–1066. 5 indexed citations
11.
Skiest, Daniel J., Amy Krambrink, Zhaohui Su, Kevin R. Robertson, & David M. Margolis. (2008). Improved Measures of Quality of Life, Lipid Profile, and Lipoatrophy After Treatment Interruption in HIV-Infected Patients With Immune Preservation: Results of ACTG 5170. JAIDS Journal of Acquired Immune Deficiency Syndromes. 49(4). 377–383. 9 indexed citations
12.
Hare, C. Bradley, John W. Mellors, Amy Krambrink, et al.. (2008). Detection of Nonnucleoside Reverse‐Transcriptase Inhibitor–Resistant HIV‐1 after Discontinuation of Virologically Suppressive Antiretroviral Therapy. Clinical Infectious Diseases. 47(3). 421–424. 24 indexed citations
13.
Gulick, Roy M., Zhaohui Su, Charles Flexner, et al.. (2007). Phase 2 Study of the Safety and Efficacy of Vicriviroc, a CCR5 Inhibitor, in HIV‐1–Infected, Treatment‐Experienced Patients: AIDS Clinical Trials Group 5211. The Journal of Infectious Diseases. 196(2). 304–312. 195 indexed citations
14.
Schackman, Bruce R., Heather J. Ribaudo, Amy Krambrink, et al.. (2007). Racial Differences in Virologic Failure Associated With Adherence and Quality of Life on Efavirenz-Containing Regimens for Initial HIV Therapy. JAIDS Journal of Acquired Immune Deficiency Syndromes. 46(5). 547–554. 55 indexed citations
15.
Skiest, Daniel J., Zhaohui Su, Diane V. Havlir, et al.. (2007). Interruption of Antiretroviral Treatment in HIV‐Infected Patients with Preserved Immune Function Is Associated with a Low Rate of Clinical Progression: A Prospective Study by AIDS Clinical Trials Group 5170. The Journal of Infectious Diseases. 195(10). 1426–1436. 51 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ann Thorkelson Breakdown of academic impact, for papers by Nitiya Chomchey Breakdown of academic impact, for papers by Rebekah Puls Breakdown of academic impact, for papers by Chris Chung Breakdown of academic impact, for papers by Frédéric Théodoro Breakdown of academic impact, for papers by Ana Canestri Breakdown of academic impact, for papers by Jerome H. Kim Breakdown of academic impact, for papers by Lourdes Adamson Breakdown of academic impact, for papers by Radjin Steingrover Breakdown of academic impact, for papers by Maria Concetta Bellocchi
Rankless by CCL
2026